Organ-chip developer Emulate raises $36M in VC funding

Emulate's lung-on-a-chip
Emulate has signed collaboration agreements with several Big Pharma companies to test the safety of drug candidates and develop chips for specific organs, diseases and processes. (Emulate)

Organ-on-a-chip developer Emulate has gathered $36 million in series C financing, and plans to expand its platform to include a wider range of disease models for drug efficacy testing.

The Boston-based company also hopes to use the proceeds to deepen the biological capabilities of its current suite of products, which mimic the physiology of the liver, intestines, lungs and brain, as well as model thrombosis and modulation of the immune system. The chips are about the size of a AA battery, and lined with microfluidic channels and living human cells and tissues.

The funding round was led by Founders Fund, with participation from ALS Investment Fund, SciFi VC, members of the GlassWall Syndicate Association and others.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The dependence of drug development on animal models for safety and efficacy testing has hit a wall,” said Aaron VanDevender, chief scientist and principal at Founders Fund, who also joined Emulate’s board of directors.

“As therapeutic approaches become ever more precise and complex, the limitations of legacy animal models increasingly prevent accurate predictions of drug responses in humans,” VanDevender said in a statement. “This crisis has simultaneously put patients at risk of unpredictable side effects while inhibiting the approval of novel life-saving therapies.”

Emulate also plans to add new collaborative, digital analysis tools to its automated platform, the Human Emulation System, which is comprised of organ chips, instrumentation and software applications.

RELATED: Emulate bumps up Series B to $45M, lands Covance deal

“At this next stage of our company’s growth, we are expanding our product portfolio, as well as building our commercial-readiness and community support team to drive integration of our platform by early adopters in the pharmaceutical industry,” said Geraldine Hamilton, Emulate’s president and chief scientific officer.

“Based on our work with pharma companies, we now keenly understand how users wish to adopt our products across the entire R&D process, from discovery to the clinic,” Hamilton said.

RELATED: Harvard spinout Emulate scores $28M, revs up marketing for organs-on-chip tech

Emulate has signed collaboration agreements with several Big Pharma companies—recently with AstraZeneca’s early development unit to use Emulate’s Liver-Chip to test the safety of drug candidates. They also plan to develop chips modeling lung tumors and renal function.

The company also has partnerships with Roche, Takeda, Merck and Johnson & Johnson, as well as a cooperative research and development agreement with the FDA and a clinical collaboration with Cedars-Sinai Medical Center.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.